See more : The Sandesh Limited (SANDESH.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Edoc Acquisition Corp. (ADOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edoc Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Marley Spoon Group SE (MS1.DE) Income Statement Analysis – Financial Results
- E&R Engineering Corporation (8027.TWO) Income Statement Analysis – Financial Results
- Gujarat Industries Power Company Limited (GIPCL.NS) Income Statement Analysis – Financial Results
- Eastern Platinum Limited (ELR.TO) Income Statement Analysis – Financial Results
- AT&T Inc. (T) Income Statement Analysis – Financial Results
Edoc Acquisition Corp. (ADOC)
About Edoc Acquisition Corp.
Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.54M | 1.80M | 0.00 |
| Gross Profit | -2.54M | -1.80M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 1.80M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.54M | 1.80M | 89.34K |
| Other Expenses | 2.54M | -70.30K | -565.30K |
| Operating Expenses | 2.54M | 1.80M | -565.30K |
| Cost & Expenses | 2.54M | 1.80M | -565.30K |
| Interest Income | 314.16K | 20.87K | 8.68K |
| Interest Expense | 36.10K | 5.03K | 0.00 |
| Depreciation & Amortization | 2.54K | 1.80K | 268.02 |
| EBITDA | -5.14K | 898.22 | -1.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.54K | -1.80K | -268.02 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.14M | 898.22K | -1.43K |
| Income Before Tax | -7.69K | -899.88 | -1.70K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.14K | 898.22 | -1.43K |
| Net Income | -7.69K | -899.88 | -1.70K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 5.93M | 11.80M | 11.80M |
| Weighted Avg Shares Out (Dil) | 5.93M | 11.80M | 11.80M |
ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2021
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce le dépôt de...
ADOCIA Announces Its Annual Results for 2021 and Presents an Update on Activities
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today its full year 2021...
ADOCIA annonce ses résultats annuels 2021 et présente un bilan de ses activités
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce aujourd'hui ses...
ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). ADOCIA SA (Paris:ADOC), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris...
Adocia: Number of Shares and Voting Rights of ADOCIA as of March 31st, 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA, (Paris:ADOC) a...
ADOCIA annonce le lancement de 3 études cliniques sur BioChaperone® Combo avec son partenaire Tonghua Dongbao
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Paris:ADOC) (Euronext Paris : FR0011184241 – ADOC – la « Société »), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres...
ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the final approval by...
ADOCIA Strengthens Its Cash Position by 19 Million Euros Following a Real Estate Transaction
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the completion of the...
ADOCIA renforce sa trésorerie de 19 millions d’euros à la suite d’une opération immobilière
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), société biopharmaceutique au stade clinique spécialisée dans la découverte et le développement de solutions thérapeutiques pour le traitement du diabète et d’autres maladies métaboliques, annonce aujourd'hui la réalisation...
Number of Shares and Voting Rights of Adocia as of February 28th, 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA, a French...
Source: https://incomestatements.info
Category: Stock Reports